Kairos Pharma, Ltd. (KAPA) Stock Price, News & Analysis

Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical-stage biopharmaceutical company in the biotechnology and healthcare sector. Based in Los Angeles, California, the company focuses on oncology therapeutics that address drug resistance and immune suppression in cancer. Kairos Pharma describes its mission as advancing targeted therapies for cancer patients with high unmet medical needs and improving the effectiveness of existing standards of care.

The company’s research centers on structural biology and mechanisms that drive resistance to cancer treatments. A core focus is CD105 (also known as endoglin), a protein identified by Kairos Pharma as a key driver of resistance to various cancer therapies. According to the company’s public statements, elevation of CD105 in response to standard therapy can lead to resistance and disease relapse. By targeting this pathway, Kairos Pharma aims to restore or extend the benefit of existing cancer treatments.

Lead program: ENV105 and CD105 antagonism

Kairos Pharma’s lead product candidate is ENV105, described as an antibody that targets CD105 and a first-in-class CD105 antagonist. The company reports that ENV105 is being evaluated in multiple clinical settings. In metastatic castration-resistant prostate cancer (mCRPC), ENV105 is being studied in combination with the hormone therapy apalutamide in a randomized Phase 2 clinical trial in men whose disease has progressed after prior hormone-based therapies. The trial is designed to assess safety, tolerability, and early signs of efficacy.

Interim analyses disclosed by the company indicate that combining ENV105 with apalutamide has shown clinical benefit in a majority of treated patients in the early cohort, with progression-free survival durations and prostate-specific antigen (PSA) reductions reported in company communications. Kairos Pharma has also highlighted that, in the interim safety analysis from the first enrolled patients, ENV105 in combination with apalutamide was well tolerated, with no dose-limiting toxicities or unexpected adverse events reported and no Grade 3 or higher toxicities observed in that dataset. These findings support continued development of ENV105 in advanced prostate cancer, according to the company.

Beyond prostate cancer, Kairos Pharma is studying ENV105 in non-small cell lung cancer (NSCLC). An open-label Phase 1 trial evaluates the safety and tolerability of ENV105 in combination with the EGFR inhibitor osimertinib in advanced EGFR‑mutated NSCLC. The company has presented initial Phase 1 data and has referenced research showing the role of CD105 in mediating resistance to osimertinib. Through this program, Kairos Pharma seeks to determine whether CD105 antagonism can help overcome or delay resistance to targeted lung cancer therapies.

Pipeline and research focus

In addition to ENV105, Kairos Pharma reports a pipeline of investigational and preclinical candidates aimed at cancer resistance and immune modulation. These include small molecule and biologic programs such as KROS101 and KROS401, which the company has discussed as potential therapeutics in areas including melanoma and glioblastoma based on preclinical data presented at scientific meetings. The company also references ENV205, described in its communications as a drug candidate intended to address chemotherapy drug resistance and cachexia.

Kairos Pharma has highlighted multiple scientific presentations and publications related to its programs, including data on ENV105 in lung and prostate cancer, a peer-reviewed publication on CD105’s role in resistance to osimertinib in EGFR‑mutant NSCLC, and preclinical findings on KROS101 and KROS401 in immuno-oncology settings. The company has also noted Department of Defense funding in support of research on ENV105 in lung cancer and ENV205 in chemotherapy resistance and cachexia.

Collaborations, licenses, and intellectual property

According to its SEC filings, Kairos Pharma has entered into novation and license arrangements that consolidate key intellectual property under the listed company. Through novation agreements, Kairos assumed exclusive license rights previously held by its wholly owned subsidiary Enviro Therapeutics, Inc. and obtained rights related to TRC105 and CD105 technologies from Tracon Pharmaceuticals, Inc. These agreements cover patents and license arrangements concerning compositions and methods for treating diseases and conditions by depletion or detection of mitochondrial or genomic DNA from circulation, and sensitization of tumors to therapies through endoglin (CD105) antagonism. Under these novation agreements, Kairos accepted and assumed the obligations and liabilities associated with the licenses, while its subsidiary was relieved of those obligations.

This licensing framework underpins Kairos Pharma’s focus on CD105-targeted therapeutics and related mechanisms of resistance. By holding these exclusive rights, the company positions ENV105 and related programs within a defined intellectual property estate that supports its development activities in prostate cancer, lung cancer, and other tumor types it has referenced in preclinical work.

Clinical development activities

Kairos Pharma’s clinical-stage efforts are concentrated on:

• Metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase 2 trial of ENV105 (carotuximab) plus apalutamide in men whose disease has progressed after hormone-based therapies. The study is enrolling patients at centers including Cedars-Sinai Medical Center, City of Hope Cancer Center, and Huntsman Cancer Institute. The company has reported interim safety and efficacy results, including progression-free survival metrics and PSA responses in the initial cohort.
• Non-small cell lung cancer: A Phase 1 open-label trial of ENV105 in combination with osimertinib in advanced EGFR‑mutated NSCLC, with the primary objective of evaluating safety and tolerability of the combination. Kairos Pharma has presented initial data from this study at a major lung cancer conference.

Through these trials, Kairos Pharma is testing whether CD105 antagonism can extend the benefit of existing therapies in settings where resistance commonly develops. The company has also indicated plans, subject to data and regulatory discussions, to consider later-stage studies, including a potential pivotal Phase 3 trial in prostate cancer, as referenced in its communications.

Corporate and capital markets profile

Kairos Pharma, Ltd. is incorporated in Delaware and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). Its common stock trades on the NYSE American exchange under the ticker symbol KAPA. The company has disclosed equity incentive plans and the use of restricted stock units (RSUs) and cash bonuses as part of its compensation structure for executives and directors, as detailed in its Form 8-K filings. These filings describe grants of RSUs that vest over time or upon certain events, such as a change in control, and outline how equity awards are used to recognize service and performance.

In addition to scientific and clinical updates, Kairos Pharma participates in investor conferences and virtual events, including presentations at the H.C. Wainwright Global Investment Conference and other forums. The company also organizes key opinion leader (KOL) events to discuss interim clinical data and the scientific rationale behind ENV105 and its broader pipeline.

Position within the biotechnology and oncology landscape

Within the biotechnology industry, Kairos Pharma identifies itself as working at the forefront of oncology therapeutics with a specific emphasis on overcoming treatment resistance and immune suppression. Rather than developing entirely new therapeutic classes in isolation, the company’s stated approach is to enhance and extend the efficacy of established standards of care, such as androgen receptor–targeted therapies in prostate cancer and EGFR inhibitors in lung cancer, by targeting mechanisms like CD105 that contribute to resistance.

By focusing on targeted therapies and resistance pathways, Kairos Pharma addresses clinical situations where patients have limited remaining treatment options after initial therapies fail. Its programs are designed to be evaluated in combination with existing drugs, reflecting a strategy centered on improving outcomes in difficult-to-treat cancers through mechanistic insights and structural biology.

Key themes for investors and observers

For investors and observers reviewing Kairos Pharma, several themes emerge from the company’s public disclosures:

• Oncology focus: All highlighted programs are directed toward cancer indications, including metastatic castration-resistant prostate cancer and non-small cell lung cancer, with preclinical work in other tumor types such as melanoma and glioblastoma.
• Resistance and immune suppression: The company’s research emphasizes mechanisms of drug resistance and immune suppression, particularly through CD105, and aims to counter these mechanisms to improve treatment durability.
• Clinical-stage status: ENV105 is in Phase 2 development in prostate cancer and Phase 1 development in lung cancer, placing Kairos Pharma firmly in the clinical-stage category within biotechnology.
• Licensed technology and IP: Through novation and license agreements with academic and corporate partners, Kairos Pharma has consolidated rights to CD105-related technologies and other patents that support its development programs.

According to its own descriptions, Kairos Pharma seeks to advance these programs through continued clinical development, scientific presentations, and engagement with the oncology and investor communities.